Psychoactive substances as a catalyst for schizophrenia – a case report

Rafał Bieś; Monika Kalicka; Ewa Martyniak; Marek Krzystanek

doi:10.5114/fpn.2025.154615

eISSN: 2449-9315
ISSN: 1234-8279

Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Standardy etyczne i procedury

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

Otwarty dostęp

1/2025
vol. 41

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

Opis przypadku

Substancje psychoaktywne jako katalizator schizofrenii – analiza przypadku

Rafał Bieś

¹

,

Monika Kalicka

²

,

Ewa Martyniak

³

,

Marek Krzystanek

³

Doctoral School, Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland
Student Scientific Association, Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Katowice, Poland
Clinic of Psychiatric Rehabilitation, Department of Psychiatry and Psychotherapy, Medical University of Silesia in Katowice, Katowice, Poland

Farmakoterapia w Psychiatrii i Neurologii 2025, 41 (1), 57-63

DOI: https://doi.org/10.5114/fpn.2025.154615

Data publikacji online: 2025/10/30

Plik artykułu:

- 6D0_IPiN_FARM_2025-1B.pdf [0.11 MB]

Pobierz cytowanie

Metryki PlumX:

1. Alharbi FF, el-Guebaly N. Cannabis and amphetamine-type stimulant-induced psychoses: a systematic overview. Addict Disord Their Treat 2016; 15 (4), 190–200.

2. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005; 187, 510–515.

3. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004; 184, 110–117.

4. Belouin SJ, Henningfield JE. Psychedelics: where we are now, why we got here, what we must do. Neuropharmacology 2018; 142, 7–19.

5. Bennett ME, Bradshaw KR, Catalano LT. Treatment of substance use disorders in schizophrenia. Am J Drug Alcohol Abuse 2017; 43, 377–390.

6. Berridge KC, Robinson TE, Aldridge JW. Dissecting components of reward: 'liking', 'wanting', and learning. Curr Opin Pharmacol 2009; 9 (1), 65–73.

7. Bloomfield MA, Ashok AH, Volkow ND, Howes OD. The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature 2016; 539 (7629), 369–377.

8. Chen WL, Hsieh CH, Chang HT, Hung CC, Chan CH. The epidemiology and progression time from transient to permanent psychiatric disorders of substance-induced psychosis in Taiwan. Addict Behav 2015; 47, 1–4.

9. Crockford D, Addington D. Canadian schizophrenia guidelines: schizophrenia and other psychotic disorders with coexisting substance use disorders. Can J Psychiatry 2017; 62, 624–634.

10. Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71 (1), 37–48.

11. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988, 85 (14), 5274–5278.

12. D’Souza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci 2009; 259 (7), 413–431.

13. Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012, 69 (8), 776–786.

14. Hunt GE, Large MM, Cleary M, Lai HM, Saunders JB. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: systematic review and meta-analysis. Drug Alcohol Depend 2018; 191, 234–258.

15. Krause M, Huhn M, Schneider-Thoma J, Bighelli I, Gutsmiedl K, Leucht S, et al. Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. Eur Neuropsychopharmacol 2018; 29, 32–45.

16. Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. Psychedelic Drugs in Biomedicine. Trends Pharmacol Sci 2017; 38 (11), 992–1005.

17. Marona-Lewicka D, Nichols CD, Nichols DE. An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology 2011; 61(3), 503–512.

18. Medford N, Baker D, Hunter E, Sierra M, Lawrence E, Phillips ML, et al. Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases. Addiction 2003; 98 (12), 1731–1736.

19. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153 (2), 199–215.

20. Somer E, Altus L, Ginzburg K. Dissociative psychopathology among opioid use disorder patients: exploring the “chemical dissociation” hypothesis. Compr Psychiatry 2010; 51 (4), 419–425.

21. Toftdahl NG, Nordentoft M, Hjorthøj C. Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study. Soc Psychiatry Psychiatr Epidemiol 2016; 51 (1), 129–140.

22. Tucker P. Substance misuse and early psychosis. Australas Psychiatry 2009; 17 (4), 291–294.

Substancje psychoaktywne jako katalizator schizofrenii – analiza przypadku

Rafał Bieś 1 , Monika Kalicka 2 , Ewa Martyniak 3 , Marek Krzystanek 3

Rafał Bieś

¹

,

Monika Kalicka

²

,

Ewa Martyniak

³

,

Marek Krzystanek

³